A phase II double-blind placebo-controlled ascending dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Other Article

Duke Authors

Cited Authors

  • Bennett-Guerrero, E; Grocott, HP; Levy, JH; Stierer, KA; Hogue, CW; Cheung, AT; Newman, MF; Carter, AA; Rossignol, DP; Collard, CD

Published Date

  • 2007

Published In

  • Anesthesia & Analgesia

Volume / Issue

  • 104 / 2

Start / End Page

  • 378 - 383